Thromboembolic Events in Castration‐Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors
ARPi demonstrated no significant effect on TE risk compared to chemotherapy, regardless of pre-existing CVD status. Similarly, when excluding patients with a prior history of TE, ARPi use remained non-significantly associated with new TE in the IPTW-adjusted competing risk analysis, highlighting the need for further investigation.
Authors
- Steven R. H. Beach (ORCID: https://orcid.org/0000-0001-8053-7761)
- Viraj A. Master (ORCID: https://orcid.org/0000-0002-7251-142X)
- Irbaz Bin Riaz (ORCID: https://orcid.org/0000-0003-4249-0311)
- Lanyu Mi (ORCID: https://orcid.org/0000-0002-6779-4568)
- Ewan K. Cobran (ORCID: https://orcid.org/0000-0002-1842-312X)
- Alan Haruo Bryce (ORCID: https://orcid.org/0000-0002-0206-3895)
- Uroj Afzal
- Sarah E. James (ORCID: https://orcid.org/0000-0002-2334-790X)
- Syed Arsalan Ahmed Naqvi (ORCID: https://orcid.org/0000-0002-3131-2088)
- Ibrahim M. Asiri (ORCID: https://orcid.org/0000-0002-0760-3280)
- Ronald C. Chen (ORCID: https://orcid.org/0000-0002-4590-8640)
Institutions
- University of Kansas (US)
- Emory University (US)
- University of Georgia (US)
- Saudi Arabian Monetary Authority (SA)
- City of Hope (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- Franklin College (US)
Publication Details
- Journal
- The Prostate
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1002/pros.24902
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- California Department of Public Health
- University of Southern California
- Centers for Disease Control and Prevention
- University of California, San Francisco
- National Cancer Institute
- National Center for Advancing Translational Sciences